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ABSTRACT
Malignant phyllodes tumor is a rare breast malignancy with sarcomatous 
overgrowth and with limited effective treatment options for recurrent and metastatic 
cases. Recent clinical trials indicated a potential for anti-angiogenic, anti-EGFR and 
immunotherapeutic approaches for patients with sarcomas, which led us to investigate 
these and other targetable pathways in malignant phyllodes tumor of the breast. 
Thirty-six malignant phyllodes tumors (including 8 metastatic tumors with two cases 
having matched primary and metastatic tumors) were profiled using gene sequencing, 
gene copy number analysis, whole genome expression, and protein expression. 
Whole genome expression analysis demonstrated consistent over-expression of 
genes involved in angiogenesis including VEGFA, Angiopoietin-2, VCAM1, PDGFRA, 
and PTTG1. EGFR protein overexpression was observed in 26/27 (96%) of cases 
with amplification of the EGFR gene in 8/24 (33%) cases. Two EGFR mutations 
were identified including EGFRvIII and a presumed pathogenic V774M mutation, 
respectively. The most common pathogenic mutations included TP53 (50%) and 
PIK3CA (15%). Cases with matched primary and metastatic tumors harbored identical 
mutations in both sites (PIK3CA/KRAS and RB1 gene mutations, respectively). Tumor 
expression of PD-L1 immunoregulatory protein was observed in 3/22 (14%) of cases. 
Overexpression of molecular biomarkers of increased angiogenesis, EGFR and immune 
checkpoints provides novel targeted therapy options in malignant phyllodes tumors 
of the breast.
INTRODUCTION
Phyllodes tumors (PT) of the breast are rare, 
biphasic (fibro-epithelial) neoplasms, constituting ≤ 1% 
of all breast cancers [1], and are histologically classified 
as benign, borderline or malignant. The malignant variant 
is characterized by an overgrowth of the malignant stromal 
(sarcomatous) component and constitutes ~20% of all 
phyllodes tumors. There is a significant potential (~22%) 
for both local recurrence and distant metastasis [1]. These 
tumors may also pose a potential therapeutic challenge as 
no effective targeted therapy has been reported yet [1, 2].
Previous studies of the molecular genetics of PT 
showed the importance of the TP53 gene and p53 protein 
in progression from benign to malignant phyllodes tumors 
[3–6]. A gene expression study conducted by Vidal et al. 
[7] revealed activation of gene clusters related to hypoxia 
and angiogenesis in malignant phyllodes cases. Expression 
of various angiogenic factors including CD34, CD105, 
vascular endothelial growth factor (VEGF) and hypoxia-
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inducible factor-alpha has also been reported in malignant 
phyllodes tumors [8–11]. Tse et al. [12] also found the 
tumor angiogenesis (measured by microvessel density) 
as an independent predictor of malignancy in phyllodes 
tumors. Recent gene sequencing studies revealed the 
presence of variety of mutations in malignant phyllodes 
tumors of which MED12 [Mediator Complex Subunit 12] 
mutation appears to be the most consistent and shared by 
both malignant and benign fibroepithelial tumors [13–15]. 
However, truly actionable (targetable by specific drugs) 
genetic alterations in PT appear to be rare. Majority of the 
previous studies showed EGFR protein overexpression and 
EGFR gene amplification in PT [13, 16–18]; However, Tse 
et al. [19] reported a low EGFR amplification rate (8%) 
in EGFR protein positive phyllodes tumors. No targetable 
EGFR activating mutations have been reported thus far.
Recently, cancer immunoediting involving immune 
check point proteins programmed cell death-1 (PD-1/
CD279) expressed on tumor infiltrating T-lymphocytes 
and its ligand (PD-L1/CD274) expressed on tumor cells 
have come into the clinical focus due the remarkable 
therapeutic benefits caused by their specific inhibitors in 
patients with advanced melanoma, renal cell carcinoma 
and non-small cell lung carcinoma [20–21]. PD-1/PD-
L1 expression was also reported in soft tissue sarcomas, 
which indicated a potential for targeting this pathway in a 
variety of cancers [20, 22–26].
In the present study, we comprehensively profiled 
a series of malignant phyllodes tumors of the breast in 
an attempt to identify potentially targetable pathways/
biomarkers.
RESULTS
Patients
The study included 36 malignant (high grade) 
phyllodes tumors of which 24 were primary, 8 metastatic 
and 4 recurrent malignant phyllodes tumors of the 
breast (Table 1). Two metastatic phyllodes cases (lung 
metastasis) had their primary site samples available for 
molecular testing. All patients were females with the mean 
age of 50.8 years (range, 17–76 years).
Tumor characteristics
EGFR status
EGFR protein overexpression (H-score ≥ 20) was 
observed in 26 of 27 tested cases (96%) while amplification 
of the EGFR gene was observed in 8 of 24 tested cases 
(33%); all EGFR amplified cases strongly overexpressed 
EGFR protein (H-score > 200) (Figure 1A–1D). EGFRvIII 
mutant variant was unequivocally detected in one out of 
29 tested cases (~3%); an additional case exhibited a 
borderline MLPA score (0.8). Both cases were primary 
phyllodes tumors overexpressing EGFR protein by IHC. 
Unequivocal EGFRvIII mutant case also harbored EGFR 
gene amplification. Activating EGFR gene mutation was 
observed in one primary phyllodes tumor (presumed 
pathogenic V774 mutation). This case also overexpressed 
EGFR protein without EGFR gene amplification or any 
other potentially targetable mutations.
Immune check-point proteins (PD-1 and PD-L1)
PD-1 and its ligand PD-L1 were evaluated in 
22 phyllodes cases. Eight cases (36%) exhibited scattered, 
below threshold PD-L1 positivity on neoplastic cells while 
3 cases including one metastatic phyllodes tumor showed 
positivity above the 5% threshold. In some cases PD-L1 
expression was also detected on mono-nuclear cells within 
and surrounding the tumor (Figure 2). PD-1 positive TILs 
were completely absent in 12 cases, while in other cases 
varied in density from 1/10 hpf to > 100/10 hpf.
Mutational profile
NGS and/or Sanger sequencing assays were 
successful in 27 cases (Table 1). Apart from the above 
described EGFR mutations, several other genes were 
mutated including: TP53 and, PIK3CA (affecting 50% 
and 15% of cases respectively), and BRCA1, BRCA2, 
RET, CDH1, MLH1, ATM, KRAS, and RB1 (all affecting 
single phyllodes cases; Table 1). Of note, two cases with 
matching primary and metastatic (lung) samples harbored 
identical mutations in both sites: case#1 affecting a 
56-year-old female had PIK3CA (H1047L) and KRAS 
(G12D) while case#2 (43-year-old female) harbored RB1 
(P347fs) gene mutation. Of note, no mutations in KDR 
(VEGFR2) were detected (n = 27).
Whole genome expression profiling
Differential expression analysis of the mRNA as 
measured by the Illumina array platform was carried out 
by comparing the normalized expression of the transcripts 
to the expression of the genes in the normal breast 
tissue. At the two fold cutoff, 247 probes representing 
243 genes were found to be up regulated and 443 probes 
representing 422 genes were found to be down regulated 
(Figure 3, Supplementary Table 1). List of upregulated 
genes includes the 57 probes (57 genes) and 19 probes 
(18 genes) that were upregulated by 5 fold. The list of 
significantly enriched Gene Ontology (GO) terms included 
terms associated with GTPase activity, cytokine binding, 
and several cell division terms.
We found that 6 angiogenic markers (VEGFA, 
Angiopoietin-2, VCAM1, PDGFRA, PTTG1, and 
CYP3A5) were differentially expressed by at least 2 fold in 
phyllodes patients when compared with control (Figure 4, 
Supplementary Table 1). Moreover, our list significantly 
overlapped with the “angiome” list as published by 
Rivera et al. [31] (17 common genes, hypergeometric test 
p-value = 0.005).
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Table 1: Results of multiplatform molecular profiling of 36 malignant phyllodes cases
Case (site) PD-L1 protein 
(IHC)
EGFR protein 
(IHC)
EGFR (ISH) EGFR 
(mutations)
NGS and Sanger (other 
mutations)
Case#1 (P) Negative Positive Negative Wild type
TP53 (G245S)
PIK3CA (H1047R)
PIK3CA (VUS G106_
R108del)
Case#2 (P) n/a Positive Negative Wild type None
Case#3 (P) Negative Positive Negative Wild type PIK3CA (H1047R)
PIK3CA (E545K)
Case#4 (P) Negative Positive Negative Wild type None
Case#5 (P) Negative Positive Negative Wild type TP53 (R248Q)
Case#6 (P) Negative Positive Negative Wild type RET (VUS S653T)
Case#7 (P) Negative Positive Negative EGFR (V774M) None
Case#8 (P) Negative Positive Negative Wild type PIK3CA (H1047L)
Case#9 (P) Negative Positive Amplified Wild type n/a
Case#10 (P) Positive Positive Negative Wild type BRCA1 (M17751)
BRCA2 (A371T, VUS)
Case#11 (P) Negative Positive Amplified Wild type n/a
Case#12 (R) Negative Positive n/a Wild type n/a
Case#13 (P) Negative Positive n/a Wild type n/a
Case#14 (P) Positive Negative Negative Wild type n/a
Case#15 (P) Positive Positive Amplified Wild type TP53 (R248W)
CDH1 (Q422K VUS)
Case#16
P
M
Negative
Positive
Positive
Positive
Negative
Negative
Wild type
Wild type
PIK3CA (H1047L), KRAS 
(G12D)
PIK3CA (H1047L), KRAS 
(G12D)
Case#17
P
M
Negative
Positive
Positive
Positive
Negative
Negative
Wild type
Wild type
RB1 (P347fs)
RB1 (P347fs)
Case#18 (R)* n/a n/a n/a n/a n/a
Case#19 (M)* n/a n/a Amplified Wild type n/a
Case#20 (P)* n/a Positive n/a n/a TP53 (T140fs) (Y234C)
Case#21 (P)* n/a n/a negative Wild type None
Case#22 (M)* n/a n/a Amplified Wild type TP53 (R282W)
Case#23 (R)* n/a Positive negative Wild type TP53 (G245S)
Case#24 (P)* n/a Positive Amplified EGFRvIII n/a
Case#25 (P)* n/a Positive Amplified Wild type TP53 (D281V)
Case#26 (M)* n/a Positive Negative Wild type TP53 (R175H)
Case#27 (M) n/a Positive Negative Wild type TP53 (V157F)
Case#28 (P) n/a Positive n/a Wild type None
(Continued )
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Case (site) PD-L1 protein 
(IHC)
EGFR protein 
(IHC)
EGFR (ISH) EGFR 
(mutations)
NGS and Sanger (other 
mutations)
Case#29 (P) n/a Positive n/a Wild type None
Case#30 (R) n/a n/a n/a n/a None
Case#31 (P) n/a Positive n/a Wild type TP53 (S99fs)
Case#32 (M) n/a n/a Negative Wild type TP53 (R175H)
Case#33 (P) Positive n/a n/a Wild type MLH1
Case#34 (P) Positive Positive n/a Wild type TP53 (L194R)
ATM (T616I)
Case#35 (P) Positive Positive Amplified Wild type TP53 (c.560–23_561del)
TP53 (R273H)
Case#36 (M) Negative Positive n/a Wild type n/a
*Gene expression profiling; IHC – immunohistochemistry; ISH – in situ hybridization; NGS – next-generation sequencing
P – Primary; R – recurrent; M – metastatic
n/a – not available
VUS – variant of unknown significance
Figure 1A-D: Primary malignant phyllodes tumor of the breast (A-B H&E stain, 10–20x magnification) with a strong 
membranous EGFR protein overexpression (C – IHC stain) accompanied by EGFR gene amplification (D – CISH).
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Figure 2: A case of metastatic phyllodes tumor to the lung with peripheral PD-L1 expression adjacent to the 
inflammatory cells and normal lung parenchyma; of note this case harbored RB1 gene mutation in both primary and 
metastatic tumor.
Figure 3: Gene expression signature of six phyllodes cases along with the normal breast tissue. In the heatmap, rows 
represent genes and columns represent samples. “Upregulated” (depicted in red) is defined as a transcript with transcript level that is > 2 
fold relative to normal breast control and down regulated (depicted in blue) is defined as a transcript with transcript level that is < 2 fold 
relative to control. The expression of the normal breast is shown in the far left column.
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DISCUSSION
Malignant phyllodes tumor of the breast is a rare 
malignancy (<1%) with a substantial potential for both 
local relapse and distant metastasis (~20%) [1]. Apart 
from surgery, no optimal treatment modalities with impact 
on overall survival are available at present [32]. Several 
recent studies indicated that molecular profiling of such 
“orphan tumors” may identify actionable targets with a 
successful outcome, even in metastatic setting [13, 22, 
33–36].
The present study using comprehensive, 
multiplatform molecular approach revealed several 
potentially targetable pathways/biomarkers in these 
neoplasms. We found upregulation of several 
angiogenesis-related genes including VEGFA, 
Angiopoietin-2, VCAM1, PDGFRA, and PTTG1 [16–19]. 
These findings may be clinically relevant as the 
upregulation of proangiogenic genes may predict response 
to the targeted therapy (e.g. angiogenesis inhibitors). We 
recently reported on a recurrent mammary angiosarcoma 
that was successfully treated with anti-angiogenic drug 
sunitinib, identified as a potentially beneficial therapy 
option using the whole genome array analysis [34]. 
In addition, anti-angiogenic targeted therapies (e.g. 
tyrosine kinase inhibitors, monoclonal antibodies) 
are promising therapeutics for the treatment of a wide 
spectrum of soft tissue tumors [37]. We also found 
overexpression of EGFR protein (with or without EGFR 
gene amplification or mutations), which could lead to the 
use of dual VEGFR/EGFR inhibitors (e.g. Vandatenib) 
or a combination of anti-VEGFR (e.g. bevacizumab) and 
anti-EGFR (e.g. erlotinib/gefitinib/cetuximab) therapies 
[38, 39]. Overexpression of PDGFRA would suggest 
the potential study of pazopanib, a multikinase inhibitor, 
with c-KIT, FGFR, PDGFR and VEGFR being amongst 
the inhibited enzymes. Of note, we report here for the 
first time that EGFRvIII (a mutant form of EGFR with 
deletion of exons 2–7 of the gene) may play a role in a 
small subset of malignant phyllodes tumors, adding this 
Figure 4: Bar plots for 6 angiogenesis markers found to be differentially regulated in Phyllodes cases when compared 
to normal breast tissue. The height represents the ratio of expression for the gene in the phyllodes case over the expression in the 
normal breast. For CYP3A5, three phyllodes cases had no detectable expression of the transcript and the values are depicted as 0 ratio. 
Normal breast expression ratio is set to ‘1’ for all 6 biomarkers and is depicted as the ‘black’ bar for all 6 genes.
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cancer to the growing list of malignancies with this type of 
mutation [40], and potentially eligible for tumor directed 
immunotherapy.
The selective mutational profiling (TSACP) of 
malignant phyllodes tumors revealed that TP53 and 
PIK3CA gene mutations are common. These results are in 
line with previous data (COSMIC database, accessed on 
July 21, 2015; [41]). In contrast to the study of Tsang et 
al. [2] who also sequenced two matched phyllodes cases 
without recurrent mutations (SMAD4, IDH1, PIK3CA, 
RET, TP53), we found identical mutational profile in both 
primary and metastatic phyllodes cases (PIK3CA/KRAS 
and RB1 gene mutations, respectively). PIK3CA and 
RB1 alterations have been already described in phyllodes 
tumors [2, 13, 42] while Tsang et al. [2] found HRAS and 
Jardim et al. [33] NRAS in a borderline, and metastatic 
phyllodes tumors, respectively. The frequency of PIK3CA 
gene mutations in our study (15%) is the highest in 
comparison with the previous data [2] and this finding 
may imply a potential therapeutic benefit of the treatment 
with mTOR inhibitors.
Recently reported expression of the two immune 
check point targetable proteins PD-1 and PD-L1 
in a variety of solid tumors including some sarcomas 
[20–26], led us to investigate them in this cohort of PT. 
Here we found that overexpression of PD-L1 characterizes 
a small subset of malignant phyllodes tumors including 
some metastatic cases, which may lead to the targeted 
immunotherapy for these patients. Numerous studies have 
reported remarkable benefits from PD-1/PD-L1 blockade 
in patients with other malignancies over-expressing PD-L1 
(e.g. renal cell carcinoma, NSCLC, malignant melanoma, 
[21, 43–44]).
Limitations of our study are related to its 
retrospective design and the small number of cases tested 
by the Illumina microarray assay. Also, further prospective 
studies should confirm the clinical relevance of profiling-
identified biomarkers.
In conclusion, this study provides additional support 
for comprehensive profiling in PT, which can identify 
several potentially targetable pathways including EGFR, 
angiogenesis, and immunotherapy for patients with locally 
advanced or metastatic tumors.
MATERIALS AND METHODS
Tissue samples
Thirty-six formalin-fixed paraffin-embedded (FFPE) 
samples of malignant phyllodes tumors were profiled at 
Caris Life Sciences, Phoenix, AZ (Molecular Intelligence 
Service™). All samples were previously diagnosed by 
referring pathologists and histologic diagnosis was 
confirmed centrally by a board certified pathologist.
Immunohistochemistry (IHC)
Expression of EGFR, PD-1 and PD-L1 was 
evaluated immunohistochemically using commercially 
available antibodies and detection kits [EGFR 
(Invitrogen); PD-1, (NAT1 antibody, Cell Marque); anti-
PD-L1 (SP142, Spring Bioscience)]. The extent of EGFR 
expression was evaluated using H-score (intensity of 
staining graded on a subjective scale of 0–3 and percentage 
of cells with given intensity were multiplied and added 
up to provide an H-score, which ranged from 0–300). 
Tumor infiltrating lymphocytes (TIL), which expressed 
PD-1 on their plasma membrane, were evaluated and their 
density (number of PD-1+ TILs per high power field) was 
recorded. Membranous expression of PD-L1 in more than 
5% of tumor cells was considered positive [20, 22–23, 27]. 
All IHC assays included positive and negative controls to 
support the validity of results.
EGFR gene alterations
Copy number changes: In-situ hybridization 
(fluorescent and chromogenic ISH)
FISH [EGFR/CEP7 probe] (Abbott Molecular/Vysis) 
and CISH (dual EGFR DNP/CEP 7 DIG probes, Ventana, 
Tucson, AZ) assays were used for evaluation of the EGFR 
gene status. EGFR gene was considered amplified if 
EGFR/CEP7 ratio > 2, or > 15 EGFR gene copies per cell 
were observed in > 10% of analyzed cells [28].
EGFRvIII mutation: fragment analysis (FA) 
sequencing and multiplex ligation-dependent 
probe amplification (MLPA)
Mutation analysis for EGFRvIII was performed on 
RNA extracted from FFPE tissue in 18 cases. Two sets 
of FAM linked primers were used to PCR amplify both 
the wild type and mutant EGFR alleles and PCR products 
were visualized using an ABI 3500xl. Signal generated 
from the wild type allele was used as an amplification 
control and samples were considered positive if EGFRvIII 
was detected at a level that is 5x typical background 
observed. Samples with EGFRvIII signals between 1–5 x 
standard background were considered indeterminate and < 
1x standard background was considered a negative result. 
This assay requires samples to have at least 50% tumor 
nuclei [29].
Eleven PTs were evaluated for EGFRvIII status 
using a multiplex ligation-dependent probe amplification 
(MLPA) assay (SALSA MLPA KIT P315-A1 EGFR, 
MRC-Holland kit, MRC-Holland, Amsterdam, 
Netherlands). Values between 0.8 - 1.5 were considered 
normal, while values < 0.8 as a loss, > 1.5 as a gain and 
values > 2 as an amplification.
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Sequencing analysis (NGS and sanger 
sequencing)
NGS was performed on genomic DNA isolated 
from FFPE samples using the Illumina MiSeq platform. 
Specific regions of the genome were amplified using the 
Illumina TruSeq Amplicon - Cancer Panel (TSACP). 
The NGS panel included 46 genes (available here: http://
www.carismolecularintelligence.com/next-generation-
sequencing-profile). All variants were detected with > 
99% confidence based on the frequency of the mutation 
present and the amplicon coverage using a mutation 
frequency threshold of 10% [23, 30]. All regions that were 
sequenced achieved a minimum of 100x coverage and 
overall samples had an average coverage of > 500x; most 
samples achieving 1000–2000x average coverage. Sanger 
Sequencing for selected regions of BRAF, KRAS, c-KIT, 
EGFR, and PIK3CA was also used.
Microarray assays
For seven cases the whole-genome expression was 
analyzed using Illumina cDNA-mediated annealing, 
selection, extension and ligation (DASL) process with 
the HumanHT-12 v4 beadChip (Illumina Inc., San 
Diego, CA). Of the seven cases run on this platform 
one case was excluded from analysis due to overall low 
scanning intensity. The 6 remaining phyllodes cases were 
normalized using mean expression normalization where 
each array data was adjusted to have the same mean as 
the control breast microarray. The ratios of expression 
for each gene were calculated by dividing the normalized 
expression of the gene to the control breast tissue. The 
detection p-value of 0.001 was used to assess if a gene 
is expressed or not. The detection p-value is an output 
of the Genome Studio software (Illumina) and represents 
the confidence that a given transcript is expressed above 
the background defined by negative control probes on 
the array. All the data analysis for gene expression was 
carried out using the Genome Studio software and the 
R Software downloaded from CRAN website (http://
cran.r-project.org).
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